Showing results (51-60 of 176) with videos related to
Sort By:
Pageof 18
JTO Clinical and Research Reports|September 15, 2020
Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of ChinaRui Fu, Lin Wu, Chao Zhang, et al.Molecular Cancer|June 14, 2013
BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplificationBen-yuan Jiang, Xu-chao Zhang, Jian Su, et al.Cancer Medicine|February 4, 2026
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 RearrangementQuan-Quan Tan, Yu-Qing Chen, Yu-Er Gao, et al.Zhonghua Yi Xue Za Zhi|January 3, 2007
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status]Chong-rui Xu, Jia-ying Lin, Zhen Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung CancerShun Lu, Jianhua Chang, Xiaoqing Liu, et al.Translational Oncology|October 29, 2021
Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression scoreSi-Yang Maggie Liu, Hao Sun, Jia-Ying Zhou, et al.Journal of Hematology & Oncology|September 14, 2016
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialQing Zhou, Jin-Ji Yang, Zhi-Hong Chen, et al.Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)Qing Zhou, Cai-cun Zhou, Gong-yan Chen, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancerJin Kang, Qiu-Mei Deng, Weineng Feng, et al.Annals of Surgical Oncology|December 5, 2012
KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapyJi-lin Guan, Wen-zhao Zhong, She-juan An, et al.Pageof 18